Hemastatx is committed to bringing innovation to patients with severe and underserved bleeding disorders. Our lead program, HMX-001, is a first-in-class antibody therapy designed to address the root cause of severe bleeding episodes in patients with von Willebrand factor (VWF) disorders.
Products, services, technology
HMX-001 is a first-in-class ADAMTS13 antibody therapy to treat severe bleeding disorders caused by excessive cleavage of VWF. This approach addresses the root cause of bleeding, and presents a pipeline-in-a-product opportunity with premium pricing and blockbuster potential.
Cooperation possibilities
HMX-001 has demonstrated in vitro and in vivo PoC, has a robust IP portfolio, and is at Lead optimization stage. We seek follow-on funding for IND-enabling studies and clinical development, or licensing opportunities.
- http://www.hemastatx.com
- +32 495 99 79 64
- Send an email
- Kevin Hollevoet
Some insights
Hemastatx is committed to bringing scientific innovation to patients with severe and underserved bleeding disorders.
We already benefit from the support of Baselaunch and their partners, but welcome continued interactions with pharma and investors.
